Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NERV
Strong SellSinkerMinerva Neurosciences, Inc. · Healthcare · United States · $231M · Avg Vol: $842K/d
COMPANY DESCRIPTION
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for central nervous system (CNS) disorders, including schizophrenia and insomnia. The company's strategy involves advancing proprietary drug candidates through clinical trials, aiming to address significant unmet needs in neuropsychiatric conditions with potentially differentiated mechanisms of action.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — |
| EPS | — | -0.69 | -0.69 | 0.03 | -34.67 | — | -36.12 |
| Shares | — | 46.6M | 46.6M | 46.6M | 43.3M | -7.1% | 47.7M |
| Debt | 0 | — | — | — | — | — | — |
| Equity | — | -20.0M | -28.5M | -25.7M | -140.7M | — | — |
| Op CF | — | -24.6M | -14.8M | -19.6M | -13.5M | — | -26.2M |
| Inv CF | 0 | -16.3K | 0 | 0 | 0 | — | — |
| Fin CF | — | -5 | 19.6M | 0 | 74.5M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NERV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NERV | Minerva Neurosciences, Inc.(you) | $231M | 11 | Strong Sell |
| RNA | Atrium Therapeutics, Inc. | $233M | 11 | Strong Sell |
| TARA | Protara Therapeutics, Inc. | $226M | 9 | Strong Sell |
| NBP | NovaBridge Biosciences | $213M | 10 | Strong Sell |
| CHRS | Coherus Oncology, Inc. | $218M | 13 | Strong Sell |
| ABOS | Acumen Pharmaceuticals, Inc. | $211M | 13 | Strong Sell |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $233M | 15 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| VYGR | Voyager Therapeutics, Inc. | $218M | 14 | Strong Sell |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $260M | 9 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%